FATE THERAPEUTICS INC Gain (Loss) on Extinguishment of Debt
FATE THERAPEUTICS INC (FATE) reported Gain (Loss) on Extinguishment of Debt of -$118.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2020-03-02
- FATE THERAPEUTICS INC gain (loss) on extinguishment of debt for the quarter ending 2017-12-31 was $0.00.
- FATE THERAPEUTICS INC gain (loss) on extinguishment of debt for the quarter ending 2017-09-30 was -$118.00K.
- FATE THERAPEUTICS INC gain (loss) on extinguishment of debt for the quarter ending 2014-12-31 was $0.00.
- FATE THERAPEUTICS INC gain (loss) on extinguishment of debt for the quarter ending 2014-09-30 was -$432.00K.
- FATE THERAPEUTICS INC gain (loss) on extinguishment of debt for fiscal 2017 was -$118.00K.
- FATE THERAPEUTICS INC gain (loss) on extinguishment of debt for fiscal 2014 was -$432.00K.
- FATE THERAPEUTICS INC gain (loss) on extinguishment of debt for fiscal 2012 was -$323.00K.
- FATE THERAPEUTICS INC gain (loss) on extinguishment of debt for fiscal 2011 was -$9.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 77 month | Gain (Loss) on Extinguishment of Debt 80 month | Gain (Loss) on Extinguishment of Debt 83 month |
|---|---|---|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$118.00K derived: sum of 2 quarters · filed 2020-03-02 | -$118.00K 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | -$118.00K 10-Q · filed 2018-11-01 | -$118.00K 10-Q · filed 2018-11-01 | |||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$432.00K derived: sum of 2 quarters · filed 2017-03-16 | -$432.00K 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | -$432.00K 10-Q · filed 2015-11-03 | -$432.00K 10-Q · filed 2015-11-03 | |||||
| 2014-03-31 | -$332.00K 10-Q · filed 2014-05-13 | ||||||
| 2013-12-31 | -$332.00K 10-K · filed 2014-03-17 | ||||||
| 2013-09-30 | -$332.00K 10-Q · filed 2013-11-13 | ||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$323.00K 10-K · filed 2015-03-12 | |||||
| 2012-09-30 | -$323.00K 10-Q · filed 2013-11-13 | ||||||
| 2011-12-31 | -$9.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |